Free tool
FAERS Monitor: Zoledronic Acid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203231 or its brand name (Zoledronic Acid, Zoledronic Acid). Reports on generic versions are filed under their own applications.
Reports
27,217
Serious
25,233
93% of reports
Hospitalization
8,992
Death reported
3,128
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- osteonecrosis of jaw2,541
- fatigue1,931
- nausea1,778
- diarrhoea1,776
- pyrexia1,668
- off label use1,602
- pain1,456
- arthralgia1,433
- neutropenia1,410
- vomiting1,409
- asthenia1,338
- malignant neoplasm progression1,202
- headache1,198
- decreased appetite1,068
- dyspnoea1,064
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 92 |
| 2006 | 108 |
| 2007 | 227 |
| 2008 | 419 |
| 2009 | 563 |
| 2010 | 324 |
| 2011 | 874 |
| 2012 | 362 |
| 2013 | 385 |
| 2014 | 431 |
| 2015 | 700 |
| 2016 | 931 |
| 2017 | 1,135 |
| 2018 | 1,718 |
| 2019 | 2,096 |
| 2020 | 2,222 |
| 2021 | 2,202 |
| 2022 | 2,342 |
| 2023 | 2,535 |
| 2024 | 2,713 |
| 2025 | 2,908 |
| 2026 | 1,889 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,942 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| osteonecrosis of jawSignal | 2,541 | 88.3 | 84.9 | 196,992 |
| malignant neoplasm progressionSignal | 1,202 | 9.2 | 8.7 | 8,676 |
| neutropeniaSignal | 1,410 | 8.1 | 7.7 | 8,716 |
| pyrexiaSignal | 1,668 | 3.7 | 3.6 | 3,383 |
| decreased appetiteSignal | 1,068 | 3.6 | 3.4 | 1,981 |
| astheniaSignal | 1,338 | 2.8 | 2.6 | 1,517 |
| arthralgiaSignal | 1,433 | 2.7 | 2.5 | 1,519 |
| vomitingSignal | 1,409 | 2.3 | 2.2 | 1,078 |
| diarrhoeaSignal | 1,776 | 2.1 | 2.0 | 1,093 |
| fatigue | 1,931 | 1.9 | 1.8 | 879 |
| pain | 1,456 | 1.8 | 1.7 | 566 |
| nausea | 1,778 | 1.7 | 1.7 | 577 |
| headache | 1,198 | 1.5 | 1.4 | 190 |
| dyspnoea | 1,064 | 1.5 | 1.4 | 154 |
| off label use | 1,602 | 1.4 | 1.3 | 202 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.